Quinoprazine 是一种强效的痘苗病毒 (Vaccinia virus) DNA合成抑制剂，IC50为 10 μM。Quinoprazine 具有抗疟活性，抑制伯氏疟原虫 (PlaSmodium berghei)。Quinoprazine 也显示出抗朊病毒效力，显著降低 PrPSc水平。

Quinoprazine is a potent inhibitor of Vaccinia virus DNA synthesis with an IC 50 value of 10 μM. Quinoprazine has antimalarial activity against Plasmodium berghei and also displays antiprion potency, significantly decreases PrP S c levels [1] - [5].

Quinoprazine shows antimalarial action against Plasmodium berghei, the chloroquine-resistant isolate LN-K65 [1]. Quinoprazine blocks Vaccinia Virus infection by inhibiting DNA synthesis [2]. Quinoprazine (IND2118) displays good antiprion potency and inhibits baseline PrP S c with reducing rates of 76% (dividing cells) and 51% (nondividing cells), respectively. Reducing PrP S c levels by >30% is considered to have good antiprion potency [3] [4]. Quinoprazine (IND2118) shows low cytotoxicity with reducing rates of 25% (dividing cells) and 24% (nondividing cells), respectively. Reducing cells<30% is considered to have a safe effect [3] [4].

Quinoprazine is a 1-alkyl-4-[4-(heterylamino)phenyl]piperazines derivate, Quinoprazine (0.25 g/kg; i.p.; single dose) suppresses the growth of larvocysts of Echinococcus multilocularis in cotton rats [5]. Quinoprazine (0.2-0.5 g/kg; p.o.; single dose) acts against the adult Hymenolepis nana. Exptl. and cures infected mice radically [5].

115618-99-0

C25H26N4

382.511

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years